Scientists have announced a significant breakthrough in the development of a drug to combat Alzheimer's disease. The drug, ...

The two FDA-approved drugs have demonstrated in clinical trials the capability to slow cognitive decline by several months, The Washington Post reported Oct. 8.

U.K. regulators will reportedly recommend that the National Health Service not cover Eli Lilly’s (NYSE:LLY) donanemab for the ...

No new treatments for schizophrenia have been approved in nearly three decades ... The company is currently studying the drug in Alzheimer’s-related psychosis, and next year plans to start ...

A groundbreaking study has unveiled a potential game-changer in the fight against Alzheimer's disease. Scientists have ...

UTHealth Houston is the first institution in Houston to administer an FDA-approved drug, Kisunla (donanemab-azbt), for the ...

Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.

FDA-approved Cobenfy offers a novel treatment for schizophrenia, targeting cholinergic receptors instead of dopamine, with ...

Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after ...

often associated with early-stage dementia. If approved by the FDA, MIRA-55 could mark a significant advancement in ...

Tribune Alzheimer’s drug disappointment. People with Down syndrome have the highest prevalence for developing Alzheimer’s ...

The U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride, or KarXT) on Sept. 26. Cobenfy is a ...